To the Editor, paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disorder of hematopoietic stem cell characterized by chronic intravascular hemolytic anemia, thrombosis, bone marrow failure, and increased susceptibility to infections. PNH is a multi-organ systemic disease, often presenting to the emergency or to the internal medicine department and requiring a multi-disciplinary approach [1,2]. The disease is due to a mutation in the phosphatidylinositol glycan class A (PIG-A) gene, resulting in a deficiency of glycosylphosphatidyl-inositol-anchored proteins (GPI-AP), including complement regulatory CD55 and CD59 proteins.
